Untitled Document
|
|
|
|
|
|
|
|
ǰǾǰó ҽ |
|
Ŵ/ħ |
3D ̿ ǰ -ü ǰ ̵
ġ ӻ ̵ ߰ |
|
ǰǾǰó(ó ) ǰǾǰ 3D ̿ ǰ ߿ ʿ ֿ 3D ̿ ǰ -ü ǰ ̵Ρ ߰ߴٰ .
ֿ 3D ̿ ǰ -ü ǰ з ǰƯм ڷ ӻ ȿ ӻ ̴.
ġ ϴ ʿ ֿ ġ ӻ ̵Ρ ߰ߴ.
ֿ ġ ڷ ġ ฮۿ뿡 ڷ ̴. |
|
|
οξȳ |
÷ܹ̿Ǿǰ [ο ȳ] |
|
ġ ġ ɻ ֹ 亯 |
|
|
/ |
2017 Ǿǰ㰡Ư㿬 |
|
5011 Ǹű, 켱Ǹǰ㰡 , å, ġ
м, Ӱ մϴ.
* () б ´(å : ) |
|
|
/ |
WHO ÷翣 , E , ̿ùз ǰ ('18.1.18) |
|
ǰǾǰó 躸DZⱸ(WHO) ̿Ǿǰ ǥȭ о ¼ͷμ , ϰ ֽϴ. ̿ Ͽ WHO Ʒ ÷翣ڹ, E ̿ùз ̵() ǰ ϰ ֽϴ.
. ÷翣 ĺ ̷ ǰ ̵
. E ǰ, ȿ Ȯ
. WHO : ̿ùз ǰ
̵ ~ٿ ǰ ִ , 2018.1.18.() ÷ε ǰ߾ļ ۼϿ ȸ(johs8739@kobia.kr) Ͽ ֽñ ٶϴ. |
|
|
ħ |
Ǿǰ Ѿ() ؼ ȹ ɻ ó ( ħ) |
|
Ǿǰ Ѿ() ؼ ȹ ɻ ó ( ħ) (rev1) |
|
|
ħ |
̿౹ Ұ ħ |
|
̿Ǿǰ, Ѿ()/Ѿ, ȭǰ, Ǿǰ, ü - ( ħ) |
|
|
|
|
̿Ǿǰ ӻ |
|
û |
|
ǰ |
|
ܰ |
ѱ
() |
20171218 |
ġ ̷ 翡 PD-L1 缺(TPS 50%) IV ̼ Ҽ ȯڸ Pembrolizumab + Ipilimumab Pembrolizumab + ϴ 3, , ߴ ӻ(KEYNOTE-598) |
3 |
MK-3475 |
ֽȸ
|
20171218 |
̽ ڿ CMV BKV Ȱȭ DNA BD03 ༺ , , 뷮, ٱ, 1 ӻ |
1 |
BD03 |
|
|
ؿ ӻ Ȳ |
|
̱ |
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
Collaborators |
Phases |
NCT03387098 |
QUILT-3.070: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Pancreatic Cancer |
Drug: Aldoxorubicin HCl|Biological: ALT-803|Biological: ETBX-011|Biological: GI-4000|Biological: haNK for infusion|Biological: avelumab|Biological: bevacizumab
...... |
NantKwest, Inc. |
Phase 1
Phase 2 |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
Metastatic Breast Cancer|HER2 Positive Breast Carcinoma |
Drug: Niraparib|Drug: Trastuzumab |
University of Alabama at Birmingham
Translational Breast Cancer Research Consortium| |
Phase 1
Phase 2 |
NCT03088878 |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma |
Drug: Cirmtuzumab|Drug: Ibrutinib|Drug: Cirmtuzumab plus ibrutinib |
University of California, San Diego
Oncternal Therapeutics, Inc |
Phase 1
Phase 2 |
NCT03368859 |
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab |
Cancer - Metastatic Colorectal |
Drug: ABT-165|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Fluorouracil - bolus|Drug: Fluorouracil - infusion |
AbbVie |
Phase 2 |
NCT03367715 |
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma |
MGMT-unmethylated Glioblastoma (GBM)|GBM |
Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy (RT) |
New York University School of Medicine |
Phase 2 |
NCT03272633 |
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|JAK2 Gene Mutation|Loss of Chromosome 17p|Mantle Cell Lymphoma|Minimal Residual Disease..... |
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Irradiated Allogeneic Cells... |
Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Phase 2 |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion|Drug: Ustekinumab SC Injection|Drug: Midazolam 2 mg|Drug: Warfarin 10 mg|Drug: Vitamin K 10 mg|Drug: Omeprazole 20 mg|Drug: Dextromethorphan 30 mg|Drug: Caffeine 100 mg |
Janssen Research & Development, LLC |
Phase 1 |
|
|
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
|
NCT03295383 |
Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid |
Severe Forms of Mucous Membrane Pemphigoid |
Drug: Rituximab 1g IV|Drug: Cyclophosphamide 50Mg Oral Tablet|Drug: Placebo of Rituximab|Drug: Placebo Oral Tablet |
University Hospital, Rouen |
Phase 3 |
|
NCT03387046 |
A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) |
Multiple Sclerosis, Relapsing-Remitting |
Dietary Supplement: D-aspartate
Drug: Placebo
Biological: IFN beta-1a
Drug: Methylprednisolone |
Merck KGaA |
Phase 2 |
|
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion|Drug: Ustekinumab SC Injection|Drug: Midazolam 2 mg|Drug: Warfarin 10 mg|Drug: Vitamin K 10 mg|Drug: Omeprazole 20 mg|Drug: Dextromethorphan 30 mg|Drug: Caffeine 100 mg |
Janssen Research & Development, LLC |
Phase 1 |
|
|
|
|
߱ |
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03380689 |
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer |
Metastatic Colorectal Cancer |
Drug: S-1|Drug: Irinotecan|Drug: Bevacizumab |
Fujian Cancer Hospital |
Phase 1 |
|
|
|
ȸ ҽ |
|
|
|
ȸ ҽ : ȸ '17 12 ߰ ڷ ȳ |
|
|
ѱ̿Ǿǰȸ 2017 ̿IT÷ ȯ
̿Ǿǰ ؿ ϱ
15 ۷ι ڷ Ͽϴ.
(̱//Ϻ/߱/ε//߽/Ű/±/ȣ/þ
/ƶ/Ʈ/εþ/Űź)
, 㰡 ü(ӻ, ǰ㰡, GMP), ϵǾ ֽϴ. |
ѱ̿Ǿǰȸ ̿Ǿǰ ڷḦ
ϰ '̿Ǿǰ ' Ͽϴ.
̿Ǿǰ Ȳ ϵǾ ֽϴ.
: Ȩ>ڷ>ȸ pdf
|
ȸ Խ ٷΰ [Click] |
Ȯϱ[Click] |
ȸ ȸ Ҽ ȸ ѵ˴ϴ. ȸ ȸ Ȯϱ (Click) |
|
|
|
|
|
û: info@kobia.kr ()
(06725) ʱ μȯ 333 10, BD 4F
COPYRIGHT(C). ѱ̿Ǿǰȸ, All Rights Reserved.
|
|
|
|